What indicators would you like to setup a trade for?

Candlestick Daily volume index Bar reversal Edit

Trade setup

Position Order Entry Exit Stop Loss Risk Return Expectancy
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

What indicators would you like to backtest?

Candlestick Daily volume index Bar reversal Edit

Backtest results

Position Trades Duration Win rate Win/loss Avg win Avg loss Return
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%



Code Company Date Close Change Indicator Value Signal

Trading Performance




Position Trades Duration Win Rate Win/Loss Avg Win Avg Loss Return
LONG 20 22.9 0.45% 0.75% 13.6% -5.5% 56.5%
SHORT 19 16.7 0.16% 0.19% 9.6% -8.8% -111.8%


Technical Analysis

Opthea (OPT.AX)



Last Signal:


Trading: BUY @ $1.805
Signal Strength: STRONG

Opthea (ASX:OPT) currently has positive MACD of 0.0118. Currently the signal line is greater than the MACD line signalling a bullish movement.

Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. This indicator has the ability to detect the speed of movement & give an early signal for a potential movement. By understanding the rate at which the price is moving in respect to the stocks historical trades, enables positions to be set in place based on changes in the speed of movement

Moving Average Convergence/Divergence (MACD) is an indicator that shows the relationship between two moving averages. It is calculated as a difference between the fast and slow moving averages. The historically popular is the difference between a securities 26-day and 12-day Exponential Moving Averages (EMA).

Calculation:: Moving Average Convergence Divergence (MACD);
1) MACD Line: (12-day EMA - 26-day EMA);
2) Signal Line: 9-day EMA of MACD Line;
3) MACD Histogram: MACD Line - Signal Line;


Stock Exchange: ASX
Company: Opthea
Ticker Codes: | OPT.AX | ASX:OPT |

About Opthea (ASX:OPT):

Opthea Limited develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) C and D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3, which is in Phase 1/2A clinical trial for the treatment of back of the eye diseases, such as wet age-related macular degeneration that is the cause of blindness in elderly and diabetic populations. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited is based in South Yarra, Australia.

Top 10:


Company Close Change(%) Volume Value Signal
BBN Baby Bunting 2.11 24.1 1,475,856 0 BULLISH CROSSOVER
SXY Senex Energy 0.17 13.8 12,737,087 0 BULLISH CROSSOVER
HLO Helloworld 1.01 8.1 576,513 0.02 BULLISH CROSSOVER
CAT Catuity 0.69 7.8 2,347,963 0.01 BULLISH CROSSOVER
JHC Japara Healthcare 0.49 7.7 887,959 0.01 BULLISH CROSSOVER
HFR Highfield Resources 0.33 6.5 18,828 0 BULLISH CROSSOVER
AQZ Alliance Aviation Services 1.4 6.1 716,836 0.02 BULLISH CROSSOVER
TLG Talga Gold 0.27 5.9 249,641 0 BULLISH CROSSOVER
ALQ ALS 5.39 5.5 3,572,301 0.05 BULLISH CROSSOVER
TNG Tennant Creek Gold 0.05 4.2 368,170 0 BULLISH CROSSOVER